For the quarter ending 2025-09-30, AUTL had -$37,709K decrease in cash & cash equivalents over the period. -$72,307K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenue-Product | 51,049 | - |
| Total revenue-License | 50 | - |
| Cost of sales | 71,039 | - |
| Research and clinical development | 45,231 | - |
| Product delivery | 15,170 | - |
| Commercial and medical affairs | 52,488 | - |
| Support functions | 60,908 | - |
| Other segment expenses, net | 4,341 | - |
| Total operating expenses | 249,177 | - |
| Loss from operations | -198,078 | - |
| Other income, net | 349 | - |
| Foreign exchange (losses) gains, net | 1,769 | - |
| Interest income | 15,753 | - |
| Interest expense, net | 13,834 | - |
| Income tax expenses | 3,155 | - |
| Net loss | -197,196 | - |
| Depreciation on property and equipment | 2,079 | 4,075 |
| Amortization of intangible assets | 459 | 570 |
| Inventory reserves and write-offs | 4,335 | 3,244 |
| Loss on disposal of property and equipment | 0 | -3 |
| Share-based compensation net of amounts capitalized | 3,835 | 7,160 |
| Interest expense accrued on liabilities related to future royalties and milestones, net | 10,493 | 3,294 |
| Accretion of available-for-sale securities | -1,690 | -5,103 |
| Foreign exchange differences | -3,219 | 5,702 |
| Amortization of right-of-use assets | 825 | 1,943 |
| Loss on termination of operating lease | 0 | - |
| Impairment of operating lease right-of-use assets and related property and equipment | 0 | - |
| Deferred income tax | -13 | -871 |
| Increase in prepaid expenses and other current assets | 18,573 | -5,452 |
| (increase) decrease in prepaid expenses and other non-current assets | -4,588 | 4,701 |
| Increase in inventories, net | 8,602 | 21,538 |
| Increase in accounts receivable, net | 6,001 | 26,726 |
| Increase in accounts payable | 5,421 | 3,395 |
| Increase in deferred revenue | 5,512 | 2,100 |
| (decrease) increase in accrued expenses and other liabilities | 2,710 | -5,237 |
| Increase (decrease) in operating lease liability | 2,593 | 6,635 |
| Net cash used in operating activities | -67,899 | -148,346 |
| Acquisition of property and equipment | 4,408 | 15,520 |
| Acquisition of intangibles assets | 8,089 | - |
| Purchases of marketable securities available-for-sale debt securities | 82,939 | 119,299 |
| Proceeds from maturities and redemptions of marketable securities available-for-sale debt securities | 130,983 | 171,187 |
| Net cash provided by (used in) investing activities | 35,547 | 36,368 |
| Proceeds of issuance of ordinary shares | 0 | 0 |
| Payments of equity issuance costs | 0 | 0 |
| Proceeds from the exercise of share options | 0 | 0 |
| Proceeds from liabilities related to future royalties and milestones, net | 0 | 0 |
| Payments of issuance costs related to the liabilities related to future royalties and milestones, net | 0 | 0 |
| Payments of revenue share | 1,774 | 768 |
| Net cash (used in) provided by financing activities | -1,774 | -768 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -3,583 | 9,273 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -37,709 | -103,473 |
| Cash and cash equivalents at beginning of period | 228,804 | - |
| Cash and cash equivalents at end of period | 87,622 | - |
Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc (AUTL)